ANTIMYCOBACTERIAL AGENTS FROM HIGHER PLANTS

描述：(改编自申请者摘要)：复发 结核病和相关的分枝杆菌疾病伴随着 艾滋病给社会带来了许多难题。结核病现在经常是 迅速致死，而且更难控制，因为现在的菌株 通常对通常用于控制它们的药物具有多重抗药性。 在这场危机中，更有可能使用的武器来源是 新型抗分枝杆菌药物的发现。使用定向筛选 方法，申请人已经鉴定出含有较高植物提取物的 结构新颖的抗分枝杆菌药物 简单、方便的化学合成导致了许多类似物的出现 对多重耐药的临床菌株和 许多其他不同的结构类型正在向类似的方向发展 测试。大量具有体外活性的提取物 抗耻垢分枝杆菌、结核分枝杆菌和禽类分枝杆菌复合体 初步研究正在等待分析。这样做的最终目的是 建议发现新的潜在的化疗药物用于治疗 分枝杆菌感染的治疗与合理用药 阶段性进入诊所。

DESCRIPTION: (Adapted from Applicant's Abstract): The recrudescence of tuberculosis and related mycobacterial diseases coupled with the rise of AIDS presents many difficult problems for society. TB is now often rapidly fatal and is more difficult to control as the strains now are often multiresistant to the drugs normally used for their control. Among the more likely sources of weapons to use in this crisis is the discovery of novel antimycobacterial agents. Using directed screening methods, the applicant has identified higher plant extracts that contain antimycobacterial agents whose structures are novel and comparatively simple, and convenient chemical synthesis has led to a number of analogs with significant activity against multiresistant clinical strains and a number of other, diverse, structural types are advancing toward similar testing. A large number of extracts that have shown in vitro activity against M. smegmatis, M. tuberculosis and M. avium complex in preliminary studies await analysis. The ultimate objective of this proposal is to discover novel potential chemotherapeutic agents for the treatment of mycobacterial infections and to advance them by logical stages into the clinic.